Evidence map›Paper›PMID 28056805›Full record

Observational studyBMC cardiovascular disorders2017

Endurance training significantly increases serum endocan but not osteoprotegerin levels: a prospective observational study.

Michael Sponder, Ioana-Alexandra Campean, Michael Emich, Monika Fritzer-Szekeres, Brigitte Litschauer, Jutta Bergler-Klein, Senta Graf, Jeanette Strametz-Juranek

Registry-linked trialAbstract readObservational Study
In one paragraph

Observational study in BMC cardiovascular disorders, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02097199 (Influence of Physical Activity on Promising Atherosclerosis Biomarkers), which is not on this map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02097199 completednot on this map

Influence of Physical Activity on Promising Atherosclerosis Biomarkers

TypeobservationalSponsorMedical University of ViennaRan2014 to 2015Enrolled98ConditionsInfluence of 8 Months of Increased Physical Activity Workload on Osteoprotegerin and Endocan LevelsArmsIncreased sports workload
3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Michael SponderMedical University of Vienna, Department of Cardiology, Währinger Gürtel 18-20, 1090, Vienna, Austria. michael.sponder@meduniwien.ac.at.ORCID 0000-0001-9016-2975
Ioana-Alexandra CampeanMedical University of Vienna, Department of Cardiology, Währinger Gürtel 18-20, 1090, Vienna, Austria.
Michael EmichAustrian Federal Ministry of Defence and Sports, Austrian Armed Forces, Brünnerstraße 238, 1210, Vienna, Austria.
Monika Fritzer-SzekeresMedical University of Vienna, Department of Medical-Chemical Laboratory Analysis, Währinger Gürtel 18-20, 1090, Vienna, Austria.
Brigitte LitschauerMedical University of Vienna, Department of Clinical Pharmacology, Währinger Gürtel 18-20, 1090, Vienna, Austria.
Jutta Bergler-KleinMedical University of Vienna, Department of Cardiology, Währinger Gürtel 18-20, 1090, Vienna, Austria.
Senta GrafMedical University of Vienna, Department of Cardiology, Währinger Gürtel 18-20, 1090, Vienna, Austria.
Jeanette Strametz-JuranekMedical University of Vienna, Department of Cardiology, Währinger Gürtel 18-20, 1090, Vienna, Austria.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundEndocan (EN) was suggested a potential inflammatory and cardiovascular disease (CVD) marker which might also be involved in renal failure and/or renal failure-associated vascular events. It is not clear whether osteoprotegerin (OPG) is a pro- or anti-atherogenic factor, however, it is agreed upon that OPG is elevated in subjects with increased calcification status. The aim of the study was to investigate the influence of long-term physical activity on serum endocan (EN) and osteoprotegerin-levels.

methodsOne hundred nine subjects were told to increase their amount of physical activity for 8 months by performing 150min/week moderate or 75min/week vigorous exercise. Incremental cycle ergometer tests were performed at the beginning and the end of the study to prove and quantify the performance gain. Blood samples were drawn at baseline and every 2 months for the determination of EN and OPG. To investigate the difference between baseline and 8 months levels of EN and OPG we used a paired sample t-test. To investigate the significance of the tendency of the progression (baseline/2 months/4 months/6 months/8 months) we used a Friedman test.

resultsThirty-eight female and 60 male subjects completed the study. In the group of 61 subjects who had a performance gain by >4,9% EN-levels increased from 146 ± 110 to 196 ± 238 pg/ml (p = 0,036) equivalent to an increase of 33,5% but there was no significant change in OPG (4,4 ± 2,4 pmol/l vs. 4,3 ± 2,1 pmol/l; p = 0,668).

conclusionsPhysical activity increases significantly EN-levels relativizing the status of EN as proinflammatory factor. EN should rather be considered as a mediator which is involved in several physiological (e.g., angiogenesis) but also pathological processes (e.g., CVD, tumour progression or endothelium-dependent inflammation) and whose expression can be significantly influenced by long term endurance training.

trial registrationClinical trial registration number: NCT02097199 Date of trial registration at Clinical Trials.gov: 24.03.2014; last update: 6.1.2016.

Indexed as

Physical EnduranceAdultAgedBiomarkersExercise TestFemaleHumansInflammation MediatorsMaleMiddle AgedNeoplasm ProteinsOsteoprotegerinProspective StudiesProteoglycansTime FactorsUp-RegulationBiomarkersESM1 protein, humanInflammation MediatorsNeoplasm ProteinsOsteoprotegerinProteoglycansTNFRSF11B protein, humanAngiogenesisCalcificationEndocanInflammationOsteoprotegerinPhysical activity

Identifiers

PMID28056805
PMCPMC5217648

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.